natgillin/translations-raw huggingface dataset:
where X1 is CONR5 or SO2NR5, reacting a compound of formula (IX) where X4 is an activated acid such as an acid chloride or SO2Cl, Ra, R3, Z1 and m are as defined in formula (I), with a compound of formula (III) as defined above; or 
gdje X1 je CONR5 ili SO2NR5, reakcijom spoja sa formulom (IX) [image] gdje X4 je aktivirana kiselina kao što je kiseli klorid ili SO2Cl, Ra, R3, Z1 i m su kako je definirano u formuli (I), sa spojem sa formulom (III) kako je gore definirano; ili
● forming a pharmaceutically acceptable salt of the compound. 
formiranje farmaceutski prihvatljive soli tog spoja.
A compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 14 for use in the treatment of allergic or viral diseases or cancers or for use in treating asthma, COPD, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, cancer, hepatitis B, hepatitis C, HIV, HPV, bacterial infections and dermatosis. 
Spoj prema formuli (I) ili njegova farmaceutski prihvatljiva sol prema bilo kojem od zahtjeva 1 do 14 naznačen time da je za uporabu kod liječenja alergijskih ili virusnih bolesti ili karcinoma ili za uporabu kod liječenja astme, COPD, alergijskog rinitisa, alergijskog konjunktivitisa, atopijskog dermatitisa, raka, hepatitisa B, hepatitisa C, HIV, HPV, bakterijskih infekcija i dermatoze.
N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide and/or a pharmaceutically effective salt thereof for use according to claim 1, wherein said use ameliorates at least one symptom of IBS-D, wherein the symptom is selected from the group consisting of abnormal sense of urgency, abnormal stool frequency, abnormal stool form, abnormal stool passage, passage of mucus and feeling of bloating or abdominal distension. 
N-metil-N-[(11S)-fenil-2-((3S)-3-hidroksipirolidin-1-il)etil]-2,2-difenilacetamid i/ili njegova farmaceutski učinkovita sol za uporabu prema patentnom zahtjevu 1, pri čemu navedena uporaba poboljšava barem jedan od simptoma IBS-D-a, gdje je simptom odabran iz grupe koja se sastoji od nenormalne potrebe za obavljanjem nužde, nenormalne učestalosti stolice, nenormalnog oblika stolice, nenormalnog prolaska stolice, prolaska sluzi i osjećaja nadimanja ili trbušnog rastezanja.
N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide and/or a pharmaceutically effective salt thereof for use according to claim 1, wherein the subject is a mammal. 
N-metil-N-[(11S)-fenil-2-((3S)-3-hidroksipirolidin-1-il)etil]-2,2-difenilacetamid i/ili njegova farmaceutski učinkovita sol za uporabu prema patentnom zahtjevu 1, pri čemu je podložni sisavac.
N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide and/or a pharmaceutically effective salt thereof for use according to claim 1, wherein the subject is a human. 
N-metil-N-[(11S)-fenil-2-((3S)-3-hidroksipirolidin-1-il)etil]-2,2-difenilacetamid i/ili njegova farmaceutski učinkovita sol za uporabu prema patentnom zahtjevu 1, pri čemu je podložni čovjek.
A marine or freshwater antifouling coating composition comprising at least one spinosyn or derivative or salt thereof and a carrier, wherein said composition is effective to prevent adhesion of aquatic organisms to articles to which said composition is applied. 
Morski ili slatkovodni pripravak antivegetativnog premaza koji sadrži najmanje jedan spinosin ili njegov derivat ili njegovu sol i nosač, naznačen time da je pripravak učinkovit za sprečavanje prianjanja vodenih organizama na predmete na koje je primijenjen navedeni pripravak.
The marine or freshwater antifouling coating composition of claim 1, wherein said carrier is chosen from a film-forming agent, cementitious material, thermoplastic material, fiberglass, elastomeric material, and vulcanized rubber. 
Morski ili slatkovodni pripravak antivegetativnog premaza prema zahtjevu 1, naznačen time da je navedeni nosač odabran od sredstva koje stvara filmski premaz, cementirajućcg materijala, termoplastičnog materijala, staklo-plastike, elastomemog materijala, te vulkanizirane gume.
The marine or freshwater antifouling coating composition of claim 1, further comprising at least one additive chosen from pigments, organic diluents, fillers, extenders, swelling agents, wetting agents, antifreezing agents, adhesion promoters, UV stabilizers, flatteners, preservatives, and combinations thereof. 
Morski ili slatkovodni pripravak antivegetativnog premaza prema zahtjevu 1, naznačen time da nadalje sadrži najmanje jedan aditiv koji je odabran od pigmenata, organskih otapala, punila, sredstava za razvlačenje, sredstava za bubrenje, sredstava za vlaženje, sredstava protiv smrzavanja, sredstava za poboljšanje adhezije, UV stabilizatora, sredstava za matiranje, konzervansa, te njihovih kombinacija.
A product comprising a submergeable marine or freshwater structure protected against fouling organisms wherein said protection is afforded by a method according to claim 16. 
Proizvod koji se sastoji od uronjive morske ili slatkovodne strukture koja je zaštićena od vegetativnih organizama naznačen time da je navedena zaštita osigurana pomoću postupka prema zahtjevu 16.
The method of claim 19, wherein the aquatic environment is a fish culture structure. 
Postupak prema zahtjevu 19, naznačen time da je vodeni okoliš struktura za uzgoj riba.
n is 3, X represents a bond, Y represents a bond, Z represents -NR3SO2R4, R3 represents a hydrogen atom, R4 represents a 5-(dimethylamino)-1-naphthyl group; or 
n je 3, X predstavlja vezu, Y predstavlja vezu, Z predstavlja -NR3SO2R4, R3 predstavlja atom vodika, R4 predstavlja skupinu 5-(dimetilamino)-1-naftila; ili
n is 3, X represents a bond, Y represents a bond, Z represents -NR3SO2R4, R3 represents a hydrogen atom, R4 represents a 4-methylphenyl group. 
n je 3, X predstavlja vezu, Y predstavlja vezu, Z predstavlja -NR3SO2R4, R3 predstavlja atom vodika, R4 predstavlja skupinu 4-metilfenila.
An immunoassay for human mature hepcidin comprising a) contacting a biological sample containing human body fluid, cell extract or tissue extract with an antibody according to any one of claims 1-4 under suitable conditions for antibody binding and allowing any mature hepcidin present to form a complex with the antibody; and b) detecting the presence or absence of the complex; and/or determining the amount of the complex in the sample by an enzyme-linked immunosorption assay (ELISA). 
Imunoispitivanje, naznačeno time što se sastoji u a) dobivanju uzorka kojeg treba ispitati za zreli ljudski hepcidin; b) stavljanju u kontakt uzorka s protutijelom u skladu s bilo kojim od patentnih zahtjeva 1-11 u uvjetima pogodnim za vezanje protutijela i koji omogućuju da sav prisutan zreli ljudski hepcidin tvori kompleks s protutijelom; i c) detektiranju prisutnosti ili odsutnosti kompleksa; i/ili određivanju količine kompleksa u uzorku postupkom imunodetekcije.
RA and RB are independently selected from the group consisting of hydrogen, alkyl, and alkylcarbonyl; and RC and RD are independently selected from the group consisting of hydrogen and alkyl. 
RA i RB su neovisno odabrani iz skupine koja se sastoji od vodika, alkila i alkikarbonila; i RC i RD su neovisno odabrani iz skupine koja se sastoji od vodika i alkila.
is selected from the group consisting of hydrogen, alkyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heteroarylalkyl, and (NRCRD)sulfonyl; and RC and RD are independently selected from the group consisting of hydrogen and alkyl. 
je odabran iz skupine koja se sastoji od vodika, alkila, arilalkila, cikloalkila, cikloalkilalkila, heterocikla, heteroarilalkila i (NRCRD)sullonila; i RC i RD su neovisno odabrani iz skupine koja se sastoji od vodika i alkila.
RA and RB are independently selected from the group consisting of hydrogen, alkyl, and alkylcarbonyl; and RC and RD are independently selected from the group consisting of hydrogen and alkyl. 
je odabran iz skupine koja se sastoji od vodika, alkila, arilalkila, cikloalkila, cikloalkilalkila, heterocikla, heteroarllalkila, i (NRCRD)sulfonila; a RC i RD su neovisno odabrani iz skupine koja se sastoji od vodika i alkila.
is selected from the group consisting of hydrogen, alkyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heteroarylalkyl, and (NTRCRD)sulfonyl; and RC and RD are independently selected from the group consisting of hydrogen and alkyl. 
je odabran iz skupine koja se sastoji od vodika, alkila. arilalkila, cikloalkila, cikloalkilalkila, heterocikla, heteroarilalkila, i (NRCRD)sulfonila; a RC i RD su neovisno odabrani iz skupine koja se sastoji od vodika i alkila.
Closing means according to any preceding claim, wherein before said cap (7) is removed from said neck (6) for the first time, said opening promoting means (28) and said further opening promoting means (29) are separated by a preset distance. 
Naprava za zatvaranje prema zahtjevu 1 ili 2, naznačena time da, prije nego što navedeni poklopac po prvi puta bude uklonjen s navedenog grla (6), navedene naprave za poticanje otvaranja (28) i navedene naprave za poticanje otvaranja (29) se odvajaju na prethodno zadanu udaljenost.
Rc is hydrogen, fluoro, or -OR5; or Ra and Rc together form a bond; 
Rc je odabrano iz grupe koja sadrži vodik, fluoro i -OR5; ili Ra i Rc zajedno formiraju vezu;
each R4 independently is hydrogen or an optionally substituted aliphatic, aryl, heteroaryl, or heterocyclyl group; or two R4 on the same nitrogen atom, taken together with the nitrogen atom, form an optionally substituted 4- to 8-membered heterocyclyl ring having, in addition to the nitrogen atom, 0-2 ring heteroatoms independently which are N, O, or S; 
svako R4 je nezavisno vodik ili opcijski supstituirana alifatična, aril, heteroaril ili heterociklil grupa; ili dva R4 na istom dušikovom atomu, zajedno sa dušikovim atomom, formiraju opcijski supstituirani 4- do 8-člani heterociklični prsten sa, pored atoma dušika, 0-2 heteroatoma u prstenu nezavisno odabrana između N, O, i S;
each R6 independently is an optionally substituted aliphatic, aryl, or heteroaryl group; and m is 1, 2, or 3; 
svaki R6 nezavisno je opcijski supstituirana alifatična, aril, ili heteroaril grupa; i m je 1, 2, ili 3;
The compound of claim 1, characterized by one or more of the following features: 
Spoj iz zahtjeva 1, naznačen time, što ima jednu ili više od slijedećih osobina:
An in vitro method of decreasing an El enzyme activity in a sample, comprising contacting the sample with a compound of any one of claims 1 to 12. 
In vitro metoda smanjivanja aktivnosti E1 enzima u uzorku, naznačena time, što podrazumijeva dovođenje u kontakt uzorka sa spojem ili njegovom farmaceutski prihvatljivom solju iz bilo kojeg od zahtjeva 1 do 10.
A compound or a pharmaceutically acceptable salt thereof of any one of claims 1 to 10, for use in treating an immune response disorder or vascular cell proliferation disorder. 
Spoj ili njegova farmaceutski prihvatljiva sol iz bilo kojeg od zahtjeva 1 do 10, naznačen time, što se koristi za liječenje poremećaja imunog odgovora ili poremećaja proliferacije vaskularnih stanica.
said chemotherapeutic agent is selected from alkylating agents, antimetabolites, cytotoxic antibiotics, adriamycin, dactinomycin, mitomycin, carminomycin, daunomycin, doxorubicin, tamoxifen, taxol, taxotere, vincristine, vinblastine, vinorelbine, etoposide (VP-16), 5-fluorouracil (5FU), cytosine arabinoside, cyclophosphamide, thiotepa, methotrexate, camptothecin, actinomycin-D, mitomycin C, cisplatin (CDDP), aminopterin, combretastatin(s), other vinca alkyloids, and derivatives or prodrugs thereof; 
Oblik prema zahtjevu 33 ili 34, gdje se to kemoterapijsko sredstvo izabire između alkilirajućih sredstava, antimetabolita, citotoksičnih antibiotika, adriamicina, daktinomicina, mitomicina, karminomicina, daunomicina, doksorubicina, tamoksifena, taksola, taksoter, vinkristina, vinblastina, vinorelbina, etopozida (VP-16), 5-fluorouracila (5FU), citozin arabinozida, ciklofosfamida, tiotepa, metotreksata, kamptotecina, aktinomicina-D, mitomicina C, cisplatina (CDDP), aminopterina, kombretastatina, drugih vinka alkaloida, i njihovih derivata ili pro-lijekova.
from an infectious disease caused by a virus selected from hepatitis type A, hepatitis type B, hepatitis type C, influenza, varicella, adenovirus, herpes simplex type 1 (HSV-1), herpes simplex type 2 (HSV-2), rinderpest, rhinovirus, echovirus, rotavirus, respiratory syncytial virus, papilloma virus, cytomegalovirus, echinovirus, arbovirus, hantavirus, coxsackie virus, mumps virus, measles virus, rubella virus, polio virus and human immunodeficiency virus type 1 or type 2 (HIV-1, HIV-2); or 
Oblik prema zahtjevu 43, gdje taj bolesnik boluje od infektivne bolesti uzrokovane virusom izabranim između hepatitia tipa A, hepatitisa tipa B, hepatitisa tipa C, influence, varicella, adenovirusa, herpesa simpleksa tipa I (HSV-1), herpesa simpleksa tipa 2 (HSV-2), rinderpesta, rinovirusa, echovirusa, rotavirusa, respiratornog sincicijskog virusa, papilloma virusa, citomegaloviruas, arbovirusa, huntavirusa, coxsackie virusa, virusa zaušnjaka, virusa ospica, rubella viruas, polio virusa ili virusa humane imunodeficijencije tipa tipa I ili tipa 2 (HIV-1, HIV-2).
An in vitro method of detecting the presence of NK cells bearing an inhibitory KIR on their cell surface in a biological sample, said method comprising the steps of: 
In vitro postupak otkrivanja prisutnosti NK stanica koje nose inhibitorni KIR na svojoj staničnoj površini u biološkom uzorku, taj postupak obuhvaća korake:
detecting the presence of said antibody in said biological sample. 
otkrivanje prisutnosti tog protutijela u biološkom uzorku.
A method of purifying from a sample NK cells bearing an inhibitory KIR on their cell surface comprising the steps of: 
Postupak pročišćavanja NK stanica iz uzorka, koje nose inhibitorni KIR na svojoj staničnoj površini, postupak obuhvaća korake:
eluting said bound NK cells from said antibody conjugated or covalently bound to a solid support. 
ispiranje tih vezanih NK stanica s protutijela ili fragmenta protutijela koje je konjugirano ili kovalento vezano za čvrstu podlogu.
Use of chitosan, a chitosan derivative or a physiologically acceptable salt thereof, for the manufacture of a formulation for the treatment of nail inflammatory diseases. 
Kitozan, naznačen time što je u vodi topljivi hidroksialkilkitozan, i/ili njegova fiziološki prihvatljiva sol, namijenjen upotrebi u liječenju upalnih bolesti noktiju.
The use according to the claim 5, wherein said active principle is selected from bethametasone, budesonide, clobetasol and salts thereof; salicylic acid, benzoic acid and salts thereof; plant extract from Equisetum arvense or Harpagophyton procumbens; diclofenac, aspirin, ketoprofen; calcipotriol, calcitriol; tretinoin, acitretin, tazarotene; cyclosporine. The use according to any of the preceding claims, wherein said formulation includes customary excipients and/or adjuvants. 
Kitozan, naznačen time što je u vodi topljivi hidroksialkilkitozan, i/ili njegova fiziološki prihvatljiva sol, namijenjen upotrebi u skladu s patentnim zahtjevom 5, gdje se navedena aktivna tvar bira između betametazona, budezonida, klobetazola i njihovih soli; salicilne kiseline, benzojeve kiseline i njihove soli; ekstrakta iz biljaka Equisetum arvense ili Harpagophyton procumbens; diklofenaka, aspirina, ketoprofena; kalcipotriola, kalcitriola; tretinoina, acitretina, tazarotena; te ciklosporina.
A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier, additive or diluent. 
Farmaceutska kompozicija naznačena time što sadrži spoj prema patentnom zahtjevu 1 i farmaceutski prihvatljiv nosač ili razblaživač.
Medicament comprising essentially at least one human Tr1 cell population directed against a human HSP. 
Lijek koji se u bitnome sastoji od najmanje jedne populacije ljudskih Tr1 stanica koji djeluje protiv ljudskog HSP-a (Heat shock proteina).
Pharmaceutical composition comprising at least one human Tr1 cell population directed against a human HSP in combination with one or more pharmaceutically acceptable carrier. 
Farmaceutski pripravak koji se sastoji od najmanje jedne populacije ljudskih Tr1 stanica koje djeluju protiv HSP-a u ljudi u kombinaciji s jednim ili više farmaceutski prihvatljivih nositelja.
A medicament or a pharmaceutical composition according to anyone of claim 1 to 3, wherein said human Tr1 cell population is directed against HSP60, HSP70, HSP90 and mixtures thereof. 
Lijek ili farmaceutski pripravak prema jednom od zahtjeva 1 do 3, naznačeni time da navedena populacija ljudskih Tr1 stanica djeluje protiv HSP60, HSP70, HSP90 i kombinacija istih.
The medicament or the pharmaceutical composition according to claim 5, wherein said inflammatory autoimmune condition is transplant rejection or Graft versus Host disease. 
Lijek ili farmaceutski pripravak prema zahtjevu 5, naznačeni time da je autoimuno upalno stanje odbijanje presatka ili reakcija transplantata protiv primatelja (GVHD).
The medicament or the pharmaceutical composition according to anyone of claims 5 to 12, wherein the medicament or pharmaceutical composition to be administered to a subject in need thereof comprises human Tr1 cells autologous to the cells of said subject. 
Lijek ili farmaceutski pripravak prema jednom od zahtjeva 5 do 12, naznačeni time da se lijek ili farmaceutski pripravak koji se daje potrebitom subjektu sastoji od Tr1 stanica koje su autologne stanicama tog subjekta.
is phenyl; phenyl substituted with 1, 2 or 3 substituents each independently selected from the group consisting of halo, cyano, C1-4alkyl, C1-4alkyloxy, perfluoroC1-4alkyl, and perfluoroC1-4alkyloxy; thienyl; thienyl substituted with 1 or 2 substituents selected from the group consisting of halo or C1-4alkyl; C1-4alkyl; or C1-4alkyl substituted with hydroxyl, C3-8cycloalkyl or and C5-7cycloalkenyl; 
je fenil; fenil supstituiran sa 1, 2 ili 3 supstituenta koji su svaki neovisno odabrani iz skupine koja sadrži halo, cijano, C1-4alkil, C1-4alkiloksi, perfluoroC1-4alkil, i perfluoroC1-4alkiloksi; tienil; tienil supstituiran sa 1 ili 2 supstituenta koji su odabrani iz skupine koja sadrži halo ili C1-4alkil; C1-4alkil; ili C1-4alkil supstituiran sa hidroksilom, C3-8cikloalkilom ili i C5-7cikloalkenilom;
The pharmaceutical composition of claim 1 or claim 2, wherein the ActRIIa-Fc fusion protein is recombinantly expressed in CHO cells using the TPA leader sequence of SEQ ID NO: 9. 
Farmaceutska smjesa iz zahtjeva 1 ili 2, naznačena time, što se ActRIIa-Fc fuzijski protein rekombinantno eksprimira u CHO stanicama, uz korištenje TPA liderske sekvence SEQ ID NO: 9.
The pharmaceutical composition of any preceding claim, wherein the dimer has 4 sialic acid moieties. 
Farmaceutska smjesa iz bilo kojeg od prethodnih zahtjeva, naznačena time, što dimer ima 4 ostatka sijalinske kiseline.
The pharmaceutical composition of any preceding claim, wherein the ActRIIa-Fc fusion protein has a serum half-life of 25 to 32 days on average in normal, healthy humans and equivalent bioavailability when administered intravenously or subcutaneously. 
Farmaceutska smjesa iz bilo kojeg od prethodnih zahtjeva, naznačena time, što ActRIIa-Fc fuzijski protein ima poluživot u serumu, kod normalnih, zdravih ljudi, u prosjeku od 25 do 32 dana, i ekvivalentnu bioraspoloživost, kada se primjeni intravenski ili subkutano.
Use of an ActRIIa-Fc fusion protein for the manufacture of a medicament for treatment or prevention of multiple myeloma in a human patient, wherein the ActRIIa-Fc fusion protein is as defined in any one of claims 1 to 10. 
Uporaba ActRIIa-Fc fuzijskog proteina, naznačena time, što se koristi za izradu lijeka za liječenje ili prevenciju multiplog mijeloma kod humanog pacijenta, pri čemu je ActRIIa-Fc fuzijski protein onakav kako je definirano u bilo kojem od zahtjeva 1 do 10.
represents C1-6 alkyl which may be substituted with phenyl, cycloalkyl, or -H, 
predstavlja C1-6 alkil koji može biti supstituiran sa sljedećima: fenil, cikloalkil ili -H,
A pharmaceutical composition comprising the compound or a pharmaceutically acceptable salt thereof of claim 1, and a pharmaceutically acceptable excipient. 
Farmaceutski sastav, naznačen time, da obuhvaća spoj ili njegovu farmaceutski prihvatljivu sol prema zahtjevu 1, te farmaceutski prihvatljivo pomoćno sredstvo.
A pharmaceutical composition for treating Alzheimer's disease, cerebrovascular dementia, Parkinson's disease, ischemic apoplexy, pain, intractable depression, attention deficit hyperactivity disorder, migraines, schizophrenia, generalized anxiety disorder, obsessive-compulsive disorder, autism, bulimia, or drug addiction, which comprises the compound or a pharmaceutically acceptable salt thereof of claim 1, or 4a-phenyl-2,3,4,4a,5,9b-hexahydro-1H-indeno[1,2-b]pyridine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. 
Farmaceutski sastav, naznačen time, da je za liječenje Alzheimer-ove bolesti, cerebrovaskularne demencije, Parkinson-ove bolesti, ishemijske apopleksije, bolova, neukrotive depresije, poremećaja hiperaktivnosti s nedostatkom pažnje, migrena, shizofrenije, poremećaja opće anksioznosti, opsesivno-kompulzivnog poremećaja, autizma, bulimije ili ovisnosti o drogama, te da obuhvaća spoj ili njegovu farmaceutski prihvatljivu sol prema zahtjevu 1, ili 4a-fenil-2,3,4,4a,5,9b-heksahidro-1H-indeno[1,2-b]piridin ili njegovu farmaceutski prihvatljivu sol kao i farmaceutski prihvatljivo pomoćno sredstvo.
Use of the compound or a pharmaceutically acceptable salt thereof of claim 1, or 4a-phenyl-2,3,4,4a,5,9b-hexahydro-1H-indeno[1,2-b]pyridine or a pharmaceutically acceptable salt thereof, for the manufacture of a pharmaceutical composition for treating Alzheimer's disease, cerebrovascular dementia, Parkinson's disease, ischemic apoplexy, pain, intractable depression, attention deficit hyperactivity disorder, migraines, schizophrenia, generalized anxiety disorder, obsessive-compulsive disorder, autism, bulimia, or drug addiction. 
Uporaba spoja ili njegove farmaceutski prihvatljive soli prema zahtjevu 1, ili 4a-fenil-2,3,4,4a,5,9b-heksahidro-1H-indeno[1,2-b]piridina ili njegove farmaceutski prihvatljive soli, naznačena time, da je za proizvodnju farmaceutskog sastava za liječenje Alzheimer-ove bolesti, cerebrovaskularne demencije, Parkinson-ove bolesti, ishemijske apopleksije, bolova, neukrotive depresije, poremećaja hiperaktivnosti s nedostatkom pažnje, migrena, shizofrenije, poremećaja opće anksioznosti, opsesivno-kompulzivnog poremećaja, autizma, bulimije ili ovisnosti o drogama.
The use of claim 14, wherein the pharmaceutical composition for treating Alzheimer's disease, cerebrovascular dementia, Parkinson's disease, ischemic apoplexy, pain, intractable depression, attention deficit hyperactivity disorder, migraines, schizophrenia, generalized anxiety disorder, obsessive-compulsive disorder, autism, bulimia, or drug addiction is a pharmaceutical composition for treating Alzheimer's disease, cerebrovascular dementia, Parkinson's disease, intractable depression, attention deficit hyperactivity disorder, or migraines. 
Uporaba prema zahtjevu 14, naznačena time, da farmaceutski sastav za liječenje Alzheimer-ove bolesti, cerebrovaskularne demencije, Parkinson-ove bolesti, ishemijske apopleksije, bolova, neukrotive depresije, poremećaja hiperaktivnosti s nedostatkom pažnje, migrena, shizofrenije, poremećaja opće anksioznosti, opsesivno-kompulzivnog poremećaja, autizma, bulimije ili ovisnosti o drogama, je farmaceutski sastav za liječenje Alzheimer-ove bolesti, cerebrovaskularne demencije, Parkinson-ove bolesti, neukrotive depresije, poremećaja hiperaktivnosti s nedostatkom pažnje ili migrena.
RA represents methyl, ethyl, or methoxy; 
predstavlja metil, etil ili metoksi;
represents hydrogen or methyl. 
predstavlja vodik ili metil.
m represents the integer 1 or 2; n represents 0, 1, or 2; and R6 represents methyl, ethyl or halogen; 
m predstavlja cijeli broj 1 ili 2; n predstavlja 0, 1 ili 2; i predstavlja metil, etil ili halogen;